AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside

Key Takeaways

• Expanded access and rapid adoption of Vafseo position Akebia for significant revenue growth and increased market share within the CKD anemia treatment landscape.
  
• Strong payer coverage, promising clinical developments, and prudent financial management support sustained profitability and enable investment in pipeline innovation.
  
• Loss of exclusivity, revenue concentration, regulatory pressures, rising costs, and increasing competition threaten pricing power, margins, and the sustainability of long-term growth.

Catalysts

A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

• Rapid expansion of Vafseo prescribing access-from 40,000 dialysis patients in early 2025 to a projected 275,000+ by late Q4 through contracts with major dialysis networks (DCI, IRC, DaVita)-positions Akebia to significantly increase near-term and long-term revenue and market share as the number of treated CKD anemia patients grows in line with an aging population and broader healthcare access.
  
• Ongoing and planned clinical trials (VOICE outcomes study in dialysis, VOCAL dosing study, upcoming VALOR Phase III for nondialysis CKD patients) are set to expand Vafseo's label and indications, which should support revenue growth, improve gross margins, and capitalize on the growing demand for personalized therapies beyond the dialysis setting.
  
• Accelerating adoption and higher refill rates-with increasing average doses and >80% of prescriptions as refills-demonstrate growing physician comfort and could drive up average revenue per patient, ultimately enhancing both topline growth and net margins.
  
• Early and broader coverage from Medicare Advantage and other payers is increasing faster than anticipated, improving reimbursement rates and expanding the effective addressable market, thus supporting sustained improvements in earnings stability and future revenue growth.
  
• Momentum in provider protocol adoption and positive initial commercial results, coupled with robust cash reserves and prudent expense management, provide Akebia the operational flexibility to invest in pipeline innovation and pursue further growth opportunities, potentially supporting long-term earnings visibility and strengthening net margins.

Akebia Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Akebia Therapeutics's revenue will grow by 2.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from -2.3% today to 8.6% in 3 years time.
• Analysts expect earnings to reach $21.7 million (and earnings per share of $0.07) by about April 2029, up from -$5.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $81.8 million in earnings, and the most bearish expecting $-3.1 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 72.7x on those 2029 earnings, up from -69.2x today. This future PE is greater than the current PE for the US Biotechs industry at 16.0x.
• Analysts expect the number of shares outstanding to grow by 2.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.0%, as per the Simply Wall St company report.

Risks

• Auryxia, a key contributor to current revenue, lost patent protection in March and already faces one authorized generic with potential for additional generics to be approved by the FDA at any time, threatening sudden and significant long-term revenue declines as generic competition erodes pricing and market share.
  
• Akebia's growth is heavily dependent on Vafseo, creating substantial revenue concentration risk; setbacks in broad adoption, physician adherence, or regulatory delays-especially in the non-dialysis CKD indication-could bring significant revenue volatility and limit sustained earnings growth.
  
• Heightened industry-wide scrutiny on drug pricing and changing government reimbursement models (Medicare/Medicaid and Medicare Advantage) could reduce net realized prices and reimbursement rates for both Vafseo and Auryxia, constraining top-line revenue growth and compressing net margins.
  
• Persistent and rising R&D and clinical trial costs, particularly for required outcomes studies like VOICE and planned large-scale VALOR trial, could strain net margins and require external funding; Akebia's history of operating losses and modest current net income raise the risk of shareholder dilution or higher-interest debt if strong cash flows are not sustained.
  
• Continued consolidation among dialysis providers and payers, combined with potential for biosimilar or competing therapies in nephrology, will strengthen counterparty negotiating leverage, increase competitive intensity, and put further downward pressure on Akebia's pricing power and long-term earnings trajectory.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $4.4 for Akebia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $3.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $252.3 million, earnings will come to $21.7 million, and it would be trading on a PE ratio of 72.7x, assuming you use a discount rate of 8.0%.
• Given the current share price of $1.38, the analyst price target of $4.4 is 68.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.